Sophiris News Releases https://investor.sophirisbio.com/ Sophiris News Releases en Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-receives-positive-feedback-european-medicines Conference call scheduled for today at 9:30 a.m. EDT SAN DIEGO and VANCOUVER, British Columbia , June 19, 2019 /PRNewswire/ -- Sophiris Bio Inc.  (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in Wed, 19 Jun 2019 08:30:00 -0400 Sophiris News Releases 8616 Sophiris Bio Reports First Quarter 2019 Financial Results https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-first-quarter-2019-financial-results SAN DIEGO and VANCOUVER, British Columbia , May 9, 2019 /PRNewswire/ --  Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of Thu, 09 May 2019 16:05:00 -0400 Sophiris News Releases 8591 Sophiris Bio to Present at Two Upcoming Investor Conferences https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-two-upcoming-investor-conferences SAN DIEGO and VANCOUVER, British Columbia , April 2, 2019 /PRNewswire/ --  Sophiris Bio Inc.  (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Tue, 02 Apr 2019 16:05:00 -0400 Sophiris News Releases 8566 Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-fourth-quarter-2018-and-year-end-financial SAN DIEGO and VANCOUVER, British Columbia , March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of Wed, 13 Mar 2019 16:05:00 -0400 Sophiris News Releases 8551 Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-provides-updates-phase-2b-localized-prostate-cancer - Reiterates plans to move to Phase 3 with single administration of topsalysin SAN DIEGO and VANCOUVER, British Columbia , Dec. 17, 2018 /PRNewswire/ --  Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, Mon, 17 Dec 2018 08:00:00 -0500 Sophiris News Releases 8516 Sophiris Bio to Present at the Piper Jaffray Healthcare Conference https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-piper-jaffray-healthcare-conference SAN DIEGO and VANCOUVER, British Columbia , Nov. 15, 2018 /PRNewswire/ -- Sophiris Bio Inc.  (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Thu, 15 Nov 2018 16:05:00 -0500 Sophiris News Releases 8491 Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2018-financial-results-and SAN DIEGO and VANCOUVER, British Columbia , Nov. 13, 2018 /PRNewswire/ --  Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Tue, 13 Nov 2018 16:05:00 -0500 Sophiris News Releases 8476 Sophiris Bio to Present at the Cantor Global Healthcare Conference https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-cantor-global-healthcare-conference SAN DIEGO and VANCOUVER, British Columbia , Sept. 25, 2018 /PRNewswire/ --  Sophiris Bio Inc.  (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Tue, 25 Sep 2018 08:00:00 -0400 Sophiris News Releases 8466 Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-extends-interest-only-period-under-its-loan-and SAN DIEGO and VANCOUVER, British Columbia, Sept. 14, 2018 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ : SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Fri, 14 Sep 2018 08:00:00 -0400 Sophiris News Releases 8451 Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-hc-wainwright-20th-annual-global-investment SAN DIEGO and VANCOUVER, British Columbia , Aug. 29, 2018 /PRNewswire/ --  Sophiris Bio Inc.  (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients Wed, 29 Aug 2018 16:30:00 -0400 Sophiris News Releases 8431